

Clean Copy of Amended Claims- Please Enter

(A marked-up copy of the claims showing the changes is attached)

A1
1. (Amended) A method for treating sexual arousal disorder comprising:
administering to a female subject in need thereof, an effective amount of an
estrogen agonist / antagonist, and optionally,
co-administering an effective amount of a cyclic guanosine 3',5'-monophosphate
elevator.

V1.1 6/29
11. (Amended) A method as in claim 10 wherein said cyclic guanosine 3',5'-
monophosphate elevator is a PDE_v phosphodiesterase inhibitor.

A2
12. (Amended) A method as in claim 11 wherein the PDE_v phosphodiesterase
inhibitor is 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-
yl)-4-ethoxy-phenyl]sufonyl]-4-methylpiperazine citrate salt.

Remarks

Applicants hereby elect to prosecute the claims of Group I, claims 1-14, which
relate to methods of treatment. Applicants have also been required to elect an "ultimate
✓ formula." Applicants hereby elect formula I of claim 2. The claims that read on formula
I are claims 1-5 and 10-12 In addition, Applicants have been required to elect a species.
✓ Applicants hereby elect the species of claim 4, which is (-)-cis-6-phenyl-5-[4-(2-
pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol. Last, Applicants
have been required to elect a disorder. Applicants hereby elect the disorder of sexual
✓ arousal disorder.

Claims 6-9 and 13-36 have been cancelled without prejudice to filing divisional
applications, as these claims relate to non-elected subject matter. Claims 1, 11 and 12
have been amended to reflect the election of sexual arousal disorder as the disorder and to
correct errors in dependencies.

Applicants believe that claims 1-5 and 10-12 are in condition for allowance.

Consideration and allowance of claims 1-5 and 10-12 is respectfully requested.

Respectfully yours,

Date: 1/25/2002

By:

Todd M. Crissey

Todd M. Crissey

Registration No. 37,807


Pfizer Inc

Eastern Point Road, MS 4159

Groton, CT 06340

Phone: (860) 715-4331

Fax: (860) 441-5221



COPY OF PAPERS
ORIGINALLY FILED

Attorney Docket No. PC10636ATMC
Application No. 09/833,169

RECEIVED

FEB 26 2002

Attachment
Marked Up Copy of Amended Claims

TECH CENTER 1600/29

1. (Amended) A method for treating [female sexual dysfunction] sexual arousal disorder comprising:
administering to a female subject in need thereof, an effective amount of an estrogen agonist / antagonist, and optionally,
co-administering an effective amount of a cyclic guanosine 3',5'-monophosphate elevator.
11. (Amended) A method as in claim [8] 10 wherein said cyclic guanosine 3',5'-monophosphate elevator is a PDE_v phosphodiesterase inhibito.
12. (Amended) A method as in claim [5] 11 [further comprising co-administrering] wherein the PDE_v phosphodiesterase inhibitor is 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-phenyl]sufonyl]-4-methylpiperazine citrate salt.